Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory breast cancer

J L Glass1, R C Frazee

  • 1Scott & White Clinic and Memorial Hospital, Temple, TX 76508.

The American Surgeon
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Multimodal therapy for inflammatory breast cancer (IBC) offers potential long-term survival for selected patients. However, this aggressive cancer subtype still carries a poor prognosis with high recurrence rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.

Leukemia·2015
Same author

Laparoscopically monitored colonoscopic polypectomy: an established form of endoluminal therapy for colorectal polyps.

Surgical endoscopy·2007
Same author

Preliminary results of a two-layered prosthetic repair for recurrent inguinal and ventral hernias combining open and laparoscopic techniques.

Hernia : the journal of hernias and abdominal wall surgery·2006
Same author

Use of porcine small intestinal submucosa as a prosthetic device for laparoscopic repair of hernias in contaminated fields: 2-year follow-up.

Hernia : the journal of hernias and abdominal wall surgery·2004
Same author

Laparoscopic diagnosis and treatment of intestinal obstruction.

Surgical endoscopy·2003
Same author

Laparoscopic ventral and incisional hernia repair: an 11-year experience.

Hernia : the journal of hernias and abdominal wall surgery·2003
Same journal

Complete Response of Merkel Cell Carcinoma to Immunotherapy and Single-Fraction Radiotherapy Following Severe COVID-19 Infection: A Case Report and Review of Immune Mechanism.

The American surgeon·2026
Same journal

Perioperative Acute Myocardial Infarction in Non-Cardiac Operations: A National Analysis.

The American surgeon·2026
Same journal

Outcomes of Completion Cholecystectomy: Association With Patient Comorbidity in a National Database.

The American surgeon·2026
Same journal

Building the Conversation: Editorial Stewardship in Contemporary Surgical Publishing.

The American surgeon·2026
Same journal

Musculoskeletal Pain in Surgeons on Operating Days.

The American surgeon·2026
Same journal

Splenectomy During Cytoreductive Surgery: Marker of Surgical Burden or Independent Predictor of Morbidity?

The American surgeon·2026
See all related articles

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Inflammatory breast cancer (IBC) historically presents a poor prognosis.
  • Multimodal treatment protocols have been developed to enhance survival rates for IBC patients.

Purpose of the Study:

  • To evaluate the outcomes of multimodal treatment for inflammatory breast cancer.
  • To assess survival rates and disease recurrence in IBC patients receiving combined therapies.

Main Methods:

  • Retrospective analysis of 23 women treated for IBC between 1979 and 1992.
  • Treatment modalities included modified radical mastectomy, chemotherapy (5-Fluorouracil, Adriamycin, Cyclophosphamide), and chest wall irradiation.
  • Assessment of clinical presentation, pathological findings, and survival data.

Main Results:

Related Experiment Videos

  • Median survival was 23.4 months (range: 6-77 months).
  • 48% of patients received chest wall irradiation, and 11 women underwent classic multimodality therapy.
  • Distant metastasis at presentation occurred in 21.7% of patients.

Conclusions:

  • Combination therapy can lead to long-term survival in select inflammatory breast cancer patients.
  • Despite aggressive treatment, the overall prognosis for IBC remains poor, with frequent disease recurrence and mortality.